Anika Therapeutics (ANIK) Operating Leases (2019 - 2026)

Anika Therapeutics (ANIK) has reported Operating Leases for 8 consecutive years, with $23.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases rose 0.61% year-over-year to $23.3 million in Q2 2026; TTM through Jun 2026 was $23.3 million, a 0.61% increase from a year earlier, with the FY2025 full-year figure at $24.2 million, up 0.76% from the prior year.
• Operating Leases was $23.3 million for Q2 2026 at Anika Therapeutics, down from $23.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $29.7 million in Q2 2022 and troughed at $18.8 million in Q1 2022.
• A 5-year average of $25.4 million and a median of $25.5 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 50.27% in 2023 and retreated 10.56% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $28.8 million in 2022, then decreased by 10.07% to $25.9 million in 2023, then decreased by 7.34% to $24.0 million in 2024, then increased by 0.76% to $24.2 million in 2025, then slipped by 3.64% to $23.3 million in 2026.
• The last three Operating Leases figures came in at $23.3 million (Q2 2026), $23.8 million (Q1 2026), and $24.2 million (Q4 2025), per Business Quant data.